As previously reported, Craig-Hallum analyst Matt Hewitt downgraded AngioDynamics to Hold from Buy, as he believes weakness seen in the last quarter in the non-BioFlo portion of the Vascular Access segment is likely to continue to weigh on revenue growth in the near-term. While there could be significant upside if the company were to obtain reimbursement for NanoKnife, it is difficult to predict the timing of reimbursement decisions, added Hewitt, who lowered his FY18 revenue estimate for AngioDynamics and cut his price target on the stock to $16 from $20.